查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2003059

PARP抑制劑藥物治療市場：按藥物、適應症、治療階段、治療環境、治療方法、患者年齡層、最終用戶和分銷管道分類——2026年至2032年全球市場預測

PARP Inhibitors Drug Therapy Market by Drug, Indication, Line Of Therapy, Treatment Setting, Therapy Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年 PARP 抑制劑藥物治療市場價值為 78 億美元，預計到 2026 年將成長至 83.3 億美元，複合年成長率為 9.88%，到 2032 年將達到 151.1 億美元。

主要市場統計數據
基準年 2025 78億美元
預計年份：2026年 83.3億美元
預測年份：2032年 151.1億美元
複合年成長率 (%) 9.88%

PARP抑制劑療法的全面應用：重點關注影響腫瘤醫學領域應用的臨床證據、監管里程碑和應用趨勢。

隨著標靶癌症治療的發展，PARP抑制劑已成為精準醫療的前沿藥物，其適應症不斷擴大，臨床應用也日益成熟。本文概述了PARP抑制的治療原理、目前這些藥物影響最大的臨床領域，以及推動其應用推廣的眾多相關人員。本文並非著眼於量化市場規模，而是聚焦於藥物的作用機制、監管里程碑和臨床終點，旨在幫助讀者更好地理解PARP抑制劑的治療背景。

對重塑 PARP 抑制劑的臨床實踐、開發策略、監管管道和獲取模式的關鍵變革性變化進行詳細分析。

在生物標記科學的進步、聯合治療的開發以及法規結構的不斷完善的推動下，PARP抑制劑療法的前景正在發生變革性變化。特別是，BRCA突變生物標記的改進以及更廣泛的同源重組缺陷特徵的出現，不僅擴大了PARP抑制劑的臨床應用範圍，也提高了患者選擇的精確度。隨著基因組分析被納入臨床決策的早期階段，臨床醫生能夠更好地識別PARP標靶治療的候選患者，並合理安排以標靶治療和免疫腫瘤藥物為中心的治療方案。

檢驗到 2025 年美國累積實施的關稅對藥品供應鏈、商業策略、准入考量和支付方參與的影響。

美國實施的累積關稅政策將持續到2025年，為醫藥供應鏈帶來了許多成本壓力，影響了採購、定價策略以及與相關人員的談判。這些關稅措施影響了活性成分的採購、成品的進口以及相關醫療用品，促使許多製造商和經銷商重新評估供應商多元化、庫存管理以及與全球合作夥伴的合約條款。製造地集中在美國境外的公司面臨獨特的壓力，需要調整其物流系統，以減輕支付方和醫療服務提供者的成本負擔。

將適應症、生物標記概況、藥物特性、治療線、治療環境和分銷管道與臨床和商業策略聯繫起來的詳細細分見解。

為了解PARP抑制劑作用於不同患者群體和臨床背景，從適應症層面進行精準的分類至關重要。在乳癌中，依受體類型進行分層可區分荷爾蒙受體陽性和三陰性乳癌，二者有不同的反應模式，並對治療順序產生不同的影響。在卵巢癌中，必須密切注意生物標記狀態，因為BRCA突變陽性、同源重組缺陷（HRD）陽性和非HRD患者群體對PARP標靶治療方法的敏感性各不相同。在胰臟癌中，基於分期的分類可區分晚期和早期患者，從而影響維持治療的可行性和臨床試驗的合格。同樣，基於分期的分類在前列腺癌中也至關重要，區分轉移性和非轉移性疾病會改變終點指標、生存預測以及與雄激素受體標靶治療治療聯合用藥的策略。

關鍵區域洞察突顯了美洲、歐洲、中東和非洲以及亞太地區在監管、診斷和支付方優先事項方面的差異如何影響 PARP 抑制劑的採用。

區域趨勢影響PARP抑制劑的研發、核准和上市，每個地區都存在獨特的臨床實踐、監管預期和支付方環境。在美洲，監管機構和支付方優先考慮療效比較和真實世界臨床表現，而臨床應用則受到成熟的基因組檢測管道和高度普及的綜合專科藥房服務的影響。這些因素共同創造了一種環境，在這種環境下，差異化的臨床證據和以支付方為中心的價值論證對治療可及性的影響尤其顯著。

本文揭示了臨床開發合作、診斷夥伴關係和商業模式如何使每家公司在 PARP 抑制劑專案上採取不同的策略。

對PARP抑制劑領域主要企業的深入檢驗揭示了它們在研發重點、臨床證據生成和商業性定位方面的策略多樣性。一些企業專注於透過基於生物標記的適應症拓展和聯合治療研究來擴大適應症範圍，而另一些企業則優先考慮安全性差異化和患者支持，以維持口服藥物的依從性。為了尋求互補的專業知識，例如將夥伴關係抑制劑與免疫腫瘤療法或血管生成抑制劑結合，以實現協同效應並分散臨床風險，策略聯盟和聯合開發夥伴關係十分常見。

為產業領導者提供實用建議，以整合生物標記策略，增強真實世界證據供應鏈的韌性，並提高支付方在 PARP 抑制劑計畫中的參與度。

產業領導者應優先採取以下幾項切實可行的措施，以提升PARP抑制劑的臨床、商業和營運績效。首先，至關重要的是將全面的生物標記策略貫穿從早期研發到商業化的整個過程。這包括支持診斷規模化、確保及時報銷檢測費用，以及投資臨床醫生教育，以縮短從診斷到治療的延誤時間。透過這些措施，企業可以提高合適患者的識別率，並提升治療啟動的效率。

這種嚴謹的調查方法詳細介紹如何整合一級和二級證據、專家訪談以及品質保證措施，以分析 PARP 抑制劑的臨床和商業性趨勢。

本分析的調查方法結合了多來源證據和定性專家見解，從而對PARP抑制劑療法提供了全面的觀點。主要調查包括對腫瘤科醫生、醫院藥劑師、專科藥房經理和保險公司顧問進行結構化訪談，以了解他們對診斷流程、治療順序和用藥障礙的實際觀點。此外，還對同行評審的臨床文獻、監管文件和指南進行了系統性回顧，以確保其與目前的臨床標準和安全性數據保持一致。

一項權威的綜合分析重點闡述了基於生物標記科學的證據生成和綜合商業化策略將如何決定 PARP 抑制劑未來的普及和影響。

總之，PARP抑制劑是一類成熟但仍在不斷發展的分子標靶癌症療法，在生物標記定義的患者群體中展現出顯著的臨床療效。未來，基因組診斷的進步、聯合治療策略的測試以及為解決支付方和醫療服務提供方的擔憂而收集的可靠真實世界數據，將共同塑造此類藥物的未來發展。相關人員必須了解區域監管和報銷政策，適應不斷變化的經銷和治療環境，並預見宏觀經濟和貿易政策變化可能帶來的供應鏈壓力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：PARP抑制劑藥物治療市場：依藥物分類

  • 細香蔥
  • 奧拉帕尼
  • 盧卡帕利
  • 塔拉索帕利

第9章：PARP抑制劑藥物治療市場：依適應症分類

  • 乳癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第10章：PARP抑制劑藥物治療市場：依治療階段分類

  • 一線治療
  • 維持治療
  • 後續治療階段

第11章 PARP抑制劑藥物治療市場：依治療環境分類

  • 住院治療
  • 門診

第12章 PARP抑制劑藥物治療市場：依治療方法分類

  • 聯合治療
  • 單藥治療

第13章：PARP抑制劑藥物治療市場：依患者年齡層別分類

  • 成人
  • 老年人

第14章 PARP抑制劑藥物治療市場：依最終用戶分類

  • 醫院
  • 零售藥房
  • 專科診所

第15章：PARP抑制劑藥物治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第16章：PARP抑制劑藥物治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 PARP抑制劑藥物治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：PARP抑制劑藥物治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國PARP抑制劑藥物治療市場

第20章：中國PARP抑制劑藥物治療市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Artios Pharma Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeiGene, Ltd.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Checkpoint Therapeutics, Inc.
  • Clovis Oncology, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Guardian Therapeutics Inc.
  • IMPACT Therapeutics
  • JEIL PHARMACEUTICAL CO., LTD.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Olympus Corporation
  • ONO PHARMACEUTICAL CO., LTD.
  • Pfizer Inc.
  • Repare Therapeutics Inc.
  • Ribon Therapeutics, Inc.
  • Sanofi SA
  • SyntheX Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zai Lab Limited
Product Code: MRR-AD517FAA716F

The PARP Inhibitors Drug Therapy Market was valued at USD 7.80 billion in 2025 and is projected to grow to USD 8.33 billion in 2026, with a CAGR of 9.88%, reaching USD 15.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.80 billion
Estimated Year [2026] USD 8.33 billion
Forecast Year [2032] USD 15.11 billion
CAGR (%) 9.88%

Comprehensive introduction to PARP inhibitor therapeutics emphasizing clinical rationale regulatory milestones and delivery dynamics shaping adoption across oncology care

The evolution of targeted oncology therapeutics has placed PARP inhibitors at the forefront of precision medicine, with expanding indications and increasing clinical sophistication. This introduction outlines the therapeutic rationale behind PARP inhibition, the current clinical corridors where these agents exert the most impact, and the broader ecosystem of stakeholders shaping their adoption. It situates readers within the therapeutic context without attempting to quantify market size, instead emphasizing mechanisms of action, regulatory landmarks, and clinical endpoints that drive decision-making.

PARP inhibitors exploit tumor-specific vulnerabilities in DNA damage repair pathways, creating synthetic lethality in cancers reliant on homologous recombination deficiencies. Their clinical utility spans several solid tumors with distinct biomarker profiles and disease stages. From initial monotherapy approvals to contemporary combination regimens and maintenance strategies, the PARP class has demonstrated durable responses in selected patient subsets and become a viable option across multiple lines of therapy. This introduction highlights those clinical inflection points and prepares the reader to understand how indication, biomarker status, and therapeutic context influence development and commercialization.

Concurrently, healthcare delivery trends-ranging from outpatient oncology infusion expansion to shifts in specialty pharmacy distribution-are reshaping how PARP inhibitors reach patients. Payer expectations and real-world evidence initiatives increasingly inform treatment algorithms, while clinician practice patterns adapt to evolving guideline recommendations. This section sets the stage for a deeper exploration of transformative shifts, segmentation nuances, regulatory and reimbursement dynamics, and practical recommendations for stakeholders seeking to navigate the complexity of PARP inhibitor deployment across therapeutic settings.

Detailed analysis of the major transformative shifts reshaping PARP inhibitor clinical practice development strategies regulatory pathways and access models

The landscape of PARP inhibitor therapy is undergoing transformative shifts driven by advances in biomarker science, combination therapy development, and evolving regulatory frameworks. Biomarker refinement, particularly around BRCA mutations and broader homologous recombination deficiency signatures, has expanded both the clinical rationale for use and the precision of patient selection. As genomic profiling becomes integrated into earlier lines of clinical decision-making, clinicians are better able to identify candidates for PARP-directed interventions and to sequence therapies around targeted and immuno-oncology agents.

Simultaneously, the therapeutic paradigm is moving from single-agent maintenance strategies to more complex combination regimens that pair PARP inhibitors with anti-angiogenics, immune checkpoint inhibitors, or cytotoxic agents. These combinations aim to broaden the responsive patient population and enhance depth of response, but they also introduce new considerations in safety management, dosing optimization, and payer negotiation. Regulatory pathways have adapted to these developments with label expansions tied to biomarker-defined populations and accelerated approvals that require robust confirmatory evidence; this regulatory dynamism influences clinical trial design and commercial planning alike.

Delivery models are shifting as well. The rise of outpatient and specialty clinic administration, coupled with expanded roles for retail and online pharmacy distribution channels, affects patient access and adherence. Real-world evidence programs and post-approval studies are increasing in importance as stakeholders seek to validate long-term outcomes, comparative effectiveness, and value propositions. Taken together, these shifts are redefining clinical pathways and commercial strategies, requiring agile cross-functional teams to align clinical development, regulatory engagement, and payer communication in order to maximize therapeutic impact.

Examination of how cumulative United States tariffs implemented through 2025 influenced pharmaceutical supply chains commercial strategies access considerations and payer engagement

The imposition of cumulative tariffs in the United States through 2025 introduced a range of cost headwinds for pharmaceutical supply chains, with implications for procurement, pricing strategies, and stakeholder negotiations. These tariff measures affected active pharmaceutical ingredient sourcing, finished product imports, and ancillary medical supplies, prompting many manufacturers and distributors to reassess supplier diversification, inventory management, and contractual terms with global partners. Companies with concentrated manufacturing footprints outside the U.S. faced discrete pressures to adapt logistics and mitigate cost pass-through to payers and providers.

In response, many stakeholders prioritized supply chain resiliency by identifying alternate manufacturing sites, nearshoring critical components, and renegotiating vendor contracts to secure longer-term price certainty. Payers and integrated delivery networks increased scrutiny on unit costs and therapy affordability, accelerating adoption of value-based contracting approaches and outcomes-based reimbursement pilots. At the provider level, institutions revisited formulary placement and chemotherapy pathway protocols to preserve therapeutic continuity while managing budgetary constraints.

Clinically, the tariff-driven environment reinforced the importance of demonstrating differential value across PARP agents, particularly where therapeutic interchangeability is debated. Real-world evidence collection and pharmacoeconomic modeling became more central to payer discussions, shaping coverage and prior authorization workflows. These collective adjustments underscore how macroeconomic and trade policies can exert downstream pressure on innovation adoption, necessitating proactive supply chain strategies, rigorous value demonstration, and collaborative engagement with payers and providers to sustain patient access during periods of external cost volatility.

In-depth segmentation insights that connect indication biomarker profiles drug characteristics lines of therapy treatment settings and distribution channels to clinical and commercial strategies

Robust segmentation is essential to understand the heterogeneous patient populations and clinical contexts in which PARP inhibitors operate, beginning with indication-level distinctions. In breast cancer, stratification by receptor type separates hormone receptor-positive disease from triple-negative disease, each with distinct responsiveness patterns and therapeutic sequencing implications. Ovarian cancer requires granular attention to biomarker status, with BRCA-mutated, homologous recombination deficiency-positive, and non-HRD cohorts showing varied sensitivity to PARP-directed approaches. Pancreatic cancer segmentation by stage distinguishes patients with advanced disease from those in earlier stages, which influences the feasibility of maintenance strategies and trial eligibility. Prostate cancer similarly pivots on stage differentiation, separating metastatic from non-metastatic disease and altering endpoints, survival expectations, and integration with androgen receptor-targeted therapies.

Drug-level differentiation among Niraparib, Olaparib, Rucaparib, and Talazoparib drives clinical positioning based on pharmacologic profiles, dosing schedules, safety signals, and approved or investigational indications. Line-of-therapy segmentation-first line, maintenance, and subsequent lines-affects objectives of treatment, whether induction of response, prolongation of progression-free intervals, or salvage therapy after resistance. Treatment setting is another critical axis: inpatient versus outpatient contexts shape administration logistics, monitoring resources, and the role of infusion centers versus oral therapy management in ambulatory oncology practices.

End users such as hospitals, retail pharmacies, and specialty clinics interact with distribution channels including hospital pharmacies, online pharmacies, and retail pharmacy networks, creating diverse access pathways and adherence touchpoints. Therapy type divides into combination therapy and monotherapy considerations, which impact safety management and payer negotiations. Finally, patient age group segmentation into adults and elderly introduces differences in comorbidity burden, polypharmacy risks, and real-world tolerability that must inform clinical protocols and patient support programs. Integrating these layered segmentation lenses supports more precise clinical trial cohorts, sharper value narratives for payers, and tailored patient support models that enhance adherence and outcomes.

Key regional insights highlighting how Americas Europe Middle East Africa and Asia-Pacific differences in regulation diagnostics and payer priorities shape PARP inhibitor adoption

Regional dynamics shape how PARP inhibitors are developed, approved, and adopted, with each geography presenting distinct clinical practices, regulatory expectations, and payer landscapes. In the Americas, regulatory authorities and payers emphasize comparative effectiveness and real-world performance, while clinical adoption is influenced by established genomic testing pathways and a high prevalence of integrated specialty pharmacy services. These factors create an environment where differentiated clinical evidence and payer-centric value demonstration are particularly influential in shaping treatment access.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and reimbursement systems requires localized evidence generation and nuanced health technology assessment engagement. Variability in genomic testing infrastructure and resource allocation means that uptake can differ substantially even within contiguous markets, driving the need for tailored access strategies, local investigator partnerships, and adaptive pricing approaches that reflect country-level health priorities. In contrast, the Asia-Pacific region presents a mix of rapidly modernizing markets with growing genomic diagnostics capacity and jurisdictions where infrastructure constraints limit the speed of adoption. This diversity necessitates a multifaceted regional strategy that balances centralized clinical development with country-specific access planning and engagement with regional key opinion leaders to support guideline inclusion and testing scale-up.

Across all regions, collaborations between industry, clinical societies, and payers to expand testing access and to integrate PARP inhibitors into standardized treatment pathways influence uptake. Cross-border clinical trial networks and data-sharing initiatives also contribute to the evidence base, enabling broader understanding of safety profiles and long-term outcomes. Recognizing and addressing regional differences in regulatory timing, diagnostic availability, and payer priorities is crucial for effective global program planning and for ensuring equitable patient access to PARP-directed therapies.

Key corporate strategic insights revealing how clinical development alliances diagnostic partnerships and commercial models differentiate company approaches to PARP inhibitor programs

A focused review of key companies active in the PARP inhibitor space reveals strategic diversity in development priorities, clinical evidence generation, and commercial positioning. Some organizations have concentrated on broadening label indications by pursuing biomarker-driven expansions and combination studies, while others emphasize safety differentiation and patient support infrastructures to maintain adherence in oral regimens. Strategic alliances and co-development partnerships have been common as firms seek complementary expertise-such as combining PARP inhibitors with immuno-oncology programs or angiogenesis inhibitors-to pursue synergistic effects and to diversify clinical risk.

Manufacturers are also investing in diagnostics partnerships to ensure upstream identification of eligible populations, recognizing that timely genomic testing is foundational to uptake. Companies with vertically integrated approaches, linking diagnostic capabilities with therapeutic offerings, are better positioned to reduce friction in the patient pathway. Competitive dynamics hinge on demonstrating robustness of data across different indications and on articulating clear value propositions that resonate with payers and providers; head-to-head evidence remains limited, so indirect comparisons and real-world analyses are increasingly used to support positioning.

Commercial strategies vary from centralized specialty pharmacy models that emphasize adherence support to broader retail distribution supported by digital patient engagement tools. Across the industry, there is a growing focus on sequencing strategies that consider prior treatments, potential cross-resistance, and tolerability profiles in older populations. These strategic variations underscore that successful execution requires alignment across clinical development, diagnostics, commercial operations, and payer engagement to translate clinical promise into sustainable patient access.

Actionable recommendations for industry leaders to integrate biomarker strategies enhance real-world evidence supply chain resilience and payer engagement for PARP inhibitor programs

Industry leaders should prioritize several actionable steps to strengthen clinical, commercial, and operational performance around PARP inhibitors. First, integrating comprehensive biomarker strategies from early development through commercialization is essential; this includes supporting diagnostic scale-up, ensuring timely test reimbursement, and investing in clinician education to reduce diagnostic-to-treatment delays. By doing so, organizations can increase identification of appropriate patients and improve the efficiency of therapeutic deployment.

Second, sponsors should pursue robust real-world evidence programs that complement clinical trials, focusing on comparative effectiveness, long-term safety, and health-related quality of life. These data will be instrumental in payer negotiations and in informing best-practice guidelines. Third, building flexible supply chains that accommodate potential trade and tariff-related disruptions enhances resilience; diversification of manufacturing sites and strategic inventory management reduce the risk of therapy shortages and price volatility.

Fourth, commercial teams must craft differentiated value narratives that address payer concerns without relying solely on list-price arguments, emphasizing measurable outcomes, reduction in downstream resource utilization, and patient-reported benefits. Fifth, consider modular patient support programs that address adherence, toxicity management, and logistics for elderly populations with comorbidities. Finally, engage early and transparently with health authorities and payers to align evidence generation with reimbursement requirements, and to design outcomes-based agreements where appropriate. Collectively, these actions foster more predictable access pathways and stronger alignment between clinical benefits and economic value.

Rigorous research methodology detailing primary and secondary evidence synthesis expert interviews and quality assurance measures used to analyze PARP inhibitor clinical and commercial dynamics

The research methodology underpinning this analysis combined a multi-source evidence synthesis with qualitative expert input to produce a comprehensive perspective on PARP inhibitor therapeutics. Primary research included structured interviews with oncology clinicians, hospital pharmacists, specialty pharmacy managers, and payer advisors to capture frontline perspectives on diagnostic workflows, treatment sequencing, and access barriers. These insights were complemented by systematic reviews of peer-reviewed clinical literature, regulatory documents, and guideline statements to ensure alignment with current clinical standards and safety data.

Secondary analysis incorporated publicly available clinical trial registries, regulatory announcements, and real-world evidence publications to track label changes, key trial outcomes, and post-approval studies. Attention was paid to heterogeneity in study populations and biomarker definitions to ensure accurate interpretation. Analytical frameworks assessed therapy positioning across lines of care, safety and tolerability trade-offs, and commercial access considerations, while scenario planning explored implications of supply chain disruptions and evolving payer expectations.

Quality assurance processes included cross-validation of interview findings against published data, triangulation of regulatory sources, and internal expert review to surface any inconsistencies or gaps. The methodology emphasized transparency about data sources and limitations, particularly where head-to-head comparative evidence remains limited, and prioritized evidence that directly informs clinical decision-making, payer dialogues, and operational planning for stakeholders involved in PARP inhibitor development and commercialization.

Conclusive synthesis highlighting how biomarker science evidence generation and integrated commercialization strategies will determine the future adoption and impact of PARP inhibitors

In conclusion, PARP inhibitors represent a mature yet evolving class of targeted oncology therapies with meaningful clinical impact in biomarker-defined populations. The trajectory of the class is shaped by advances in genomic diagnostics, strategic combination trials, and the need for compelling real-world evidence to address payer and provider questions. Stakeholders must navigate region-specific regulatory and reimbursement landscapes, adapt to shifts in distribution and treatment settings, and anticipate supply chain pressures that may arise from macroeconomic and trade policy changes.

Success in this environment depends on integrated strategies that connect diagnostics, clinical development, and commercial execution. Prioritizing patient identification through reliable testing pathways, investing in evidence that demonstrates value beyond surrogate endpoints, and designing patient-centric support programs will collectively enhance adoption and long-term treatment continuity. Collaborative approaches involving industry, clinical societies, payers, and healthcare providers can accelerate guideline incorporation and broaden appropriate access while maintaining fiscal sustainability.

Ultimately, the continued evolution of PARP inhibitor therapy will be determined by the strength of biomarker science, the ability to demonstrate meaningful clinical and real-world outcomes, and the agility of organizations to align manufacturing, distribution, and payer engagement with rapidly changing clinical needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PARP Inhibitors Drug Therapy Market, by Drug

  • 8.1. Niraparib
  • 8.2. Olaparib
  • 8.3. Rucaparib
  • 8.4. Talazoparib

9. PARP Inhibitors Drug Therapy Market, by Indication

  • 9.1. Breast Cancer
  • 9.2. Ovarian Cancer
  • 9.3. Pancreatic Cancer
  • 9.4. Prostate Cancer

10. PARP Inhibitors Drug Therapy Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Maintenance
  • 10.3. Subsequent Line

11. PARP Inhibitors Drug Therapy Market, by Treatment Setting

  • 11.1. Inpatient
  • 11.2. Outpatient

12. PARP Inhibitors Drug Therapy Market, by Therapy Type

  • 12.1. Combination Therapy
  • 12.2. Monotherapy

13. PARP Inhibitors Drug Therapy Market, by Patient Age Group

  • 13.1. Adults
  • 13.2. Elderly

14. PARP Inhibitors Drug Therapy Market, by End User

  • 14.1. Hospitals
  • 14.2. Retail Pharmacies
  • 14.3. Specialty Clinics

15. PARP Inhibitors Drug Therapy Market, by Distribution Channel

  • 15.1. Hospital Pharmacies
  • 15.2. Online Pharmacies
  • 15.3. Retail Pharmacies

16. PARP Inhibitors Drug Therapy Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. PARP Inhibitors Drug Therapy Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. PARP Inhibitors Drug Therapy Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States PARP Inhibitors Drug Therapy Market

20. China PARP Inhibitors Drug Therapy Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc.
  • 21.6. Amgen Inc.
  • 21.7. Artios Pharma Ltd.
  • 21.8. Astellas Pharma Inc.
  • 21.9. AstraZeneca plc
  • 21.10. Bayer AG
  • 21.11. BeiGene, Ltd.
  • 21.12. Biogen Inc.
  • 21.13. Bristol-Myers Squibb Company
  • 21.14. Checkpoint Therapeutics, Inc.
  • 21.15. Clovis Oncology, Inc.
  • 21.16. Daiichi Sankyo Company, Limited
  • 21.17. Eisai Co., Ltd.
  • 21.18. Eli Lilly and Company
  • 21.19. F. Hoffmann-La Roche Ltd.
  • 21.20. Genentech, Inc.
  • 21.21. GlaxoSmithKline plc
  • 21.22. Guardian Therapeutics Inc.
  • 21.23. IMPACT Therapeutics
  • 21.24. JEIL PHARMACEUTICAL CO., LTD.
  • 21.25. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 21.26. Johnson & Johnson Services, Inc.
  • 21.27. Karyopharm Therapeutics Inc.
  • 21.28. Kyowa Kirin Co., Ltd.
  • 21.29. Merck & Co., Inc.
  • 21.30. Merck KGaA
  • 21.31. Myriad Genetics, Inc.
  • 21.32. Novartis AG
  • 21.33. Olympus Corporation
  • 21.34. ONO PHARMACEUTICAL CO., LTD.
  • 21.35. Pfizer Inc.
  • 21.36. Repare Therapeutics Inc.
  • 21.37. Ribon Therapeutics, Inc.
  • 21.38. Sanofi S.A.
  • 21.39. SyntheX Inc.
  • 21.40. Takeda Pharmaceutical Company Limited
  • 21.41. Teva Pharmaceutical Industries Ltd.
  • 21.42. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 164. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 167. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 191. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 194. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 200. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 203. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)